 Marino Resendiz
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA | 11 | 2026 | 926 | 2.920 |
Why?
| | Guanosine | 5 | 2024 | 40 | 1.780 |
Why?
| | Aptamers, Nucleotide | 3 | 2025 | 86 | 1.540 |
Why?
| | Guanine | 3 | 2025 | 85 | 1.540 |
Why?
| | Adenosine | 3 | 2020 | 255 | 1.400 |
Why?
| | Nucleic Acid Conformation | 8 | 2025 | 728 | 1.330 |
Why?
| | Ribonucleases | 2 | 2026 | 49 | 1.080 |
Why?
| | RNA Stability | 2 | 2026 | 119 | 0.920 |
Why?
| | Oligonucleotides | 2 | 2018 | 151 | 0.920 |
Why?
| | Aminoglycosides | 1 | 2025 | 30 | 0.910 |
Why?
| | Circular Dichroism | 4 | 2018 | 144 | 0.840 |
Why?
| | Inosine | 2 | 2020 | 14 | 0.820 |
Why?
| | Thiophenes | 2 | 2017 | 121 | 0.740 |
Why?
| | Avian Myeloblastosis Virus | 1 | 2020 | 4 | 0.650 |
Why?
| | Moloney murine leukemia virus | 1 | 2020 | 13 | 0.650 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 2020 | 35 | 0.650 |
Why?
| | HIV Reverse Transcriptase | 1 | 2020 | 31 | 0.650 |
Why?
| | Theophylline | 1 | 2020 | 41 | 0.620 |
Why?
| | DNA | 3 | 2022 | 1447 | 0.570 |
Why?
| | Ribonuclease T1 | 1 | 2018 | 5 | 0.560 |
Why?
| | Ribonuclease H | 1 | 2018 | 12 | 0.560 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2018 | 10 | 0.550 |
Why?
| | Oligoribonucleotides | 1 | 2017 | 52 | 0.510 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2017 | 140 | 0.500 |
Why?
| | Uridine | 2 | 2012 | 30 | 0.440 |
Why?
| | Adenine | 1 | 2017 | 337 | 0.420 |
Why?
| | Oxidation-Reduction | 5 | 2026 | 1078 | 0.410 |
Why?
| | Biological Products | 1 | 2017 | 256 | 0.390 |
Why?
| | Hydrogen Bonding | 2 | 2025 | 169 | 0.380 |
Why?
| | Photolysis | 2 | 2012 | 94 | 0.370 |
Why?
| | Base Sequence | 4 | 2022 | 2177 | 0.350 |
Why?
| | RNA, Double-Stranded | 1 | 2012 | 56 | 0.350 |
Why?
| | Sulfides | 1 | 2012 | 92 | 0.340 |
Why?
| | Pyrimidines | 2 | 2012 | 519 | 0.340 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2022 | 141 | 0.320 |
Why?
| | Molecular Structure | 4 | 2020 | 495 | 0.300 |
Why?
| | Pentanones | 1 | 2007 | 3 | 0.270 |
Why?
| | Ketones | 1 | 2007 | 53 | 0.250 |
Why?
| | Pyrrolidines | 1 | 2007 | 123 | 0.250 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2020 | 625 | 0.230 |
Why?
| | Polyribonucleotide Nucleotidyltransferase | 1 | 2024 | 1 | 0.220 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 384 | 0.220 |
Why?
| | Oxidative Stress | 2 | 2024 | 1338 | 0.220 |
Why?
| | Phenanthrolines | 1 | 2004 | 8 | 0.210 |
Why?
| | Molecular Probe Techniques | 1 | 2004 | 8 | 0.210 |
Why?
| | Chromium | 1 | 2004 | 16 | 0.210 |
Why?
| | Cadmium | 1 | 2004 | 68 | 0.200 |
Why?
| | Catalytic Domain | 1 | 2024 | 231 | 0.200 |
Why?
| | Photochemistry | 3 | 2009 | 131 | 0.200 |
Why?
| | Nickel | 1 | 2004 | 62 | 0.200 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.180 |
Why?
| | Free Radicals | 3 | 2012 | 110 | 0.180 |
Why?
| | Models, Molecular | 4 | 2012 | 1610 | 0.160 |
Why?
| | Base Pairing | 1 | 2020 | 65 | 0.160 |
Why?
| | Templates, Genetic | 1 | 2020 | 63 | 0.160 |
Why?
| | DNA, Complementary | 1 | 2020 | 273 | 0.160 |
Why?
| | Escherichia coli | 1 | 2024 | 854 | 0.150 |
Why?
| | Pyridines | 1 | 2004 | 603 | 0.150 |
Why?
| | Models, Chemical | 1 | 2020 | 264 | 0.150 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1046 | 0.140 |
Why?
| | Kinetics | 2 | 2020 | 1602 | 0.140 |
Why?
| | Thermodynamics | 1 | 2020 | 425 | 0.140 |
Why?
| | Models, Genetic | 1 | 2020 | 531 | 0.140 |
Why?
| | Solid-Phase Synthesis Techniques | 1 | 2017 | 10 | 0.130 |
Why?
| | Transition Temperature | 1 | 2017 | 28 | 0.130 |
Why?
| | Substrate Specificity | 1 | 2018 | 392 | 0.130 |
Why?
| | Inverted Repeat Sequences | 1 | 2017 | 18 | 0.130 |
Why?
| | Purine Nucleotides | 1 | 2017 | 12 | 0.130 |
Why?
| | Spectrophotometry | 1 | 2017 | 56 | 0.130 |
Why?
| | Organophosphorus Compounds | 1 | 2017 | 84 | 0.120 |
Why?
| | RNA, Viral | 1 | 2020 | 689 | 0.120 |
Why?
| | Video Recording | 1 | 2017 | 217 | 0.120 |
Why?
| | Pyrimidinones | 1 | 2017 | 125 | 0.120 |
Why?
| | Pyrroles | 1 | 2017 | 213 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1928 | 0.110 |
Why?
| | Animals | 3 | 2026 | 37948 | 0.090 |
Why?
| | Stereoisomerism | 2 | 2009 | 102 | 0.080 |
Why?
| | Riboswitch | 1 | 2012 | 63 | 0.080 |
Why?
| | Humans | 7 | 2026 | 144667 | 0.080 |
Why?
| | Hydroxyl Radical | 1 | 2010 | 94 | 0.070 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2004 | 238 | 0.070 |
Why?
| | Crystallography, X-Ray | 2 | 2007 | 491 | 0.070 |
Why?
| | Powder Diffraction | 1 | 2007 | 3 | 0.070 |
Why?
| | Cyclization | 1 | 2007 | 22 | 0.070 |
Why?
| | Molecular Conformation | 1 | 2007 | 147 | 0.060 |
Why?
| | DNA Damage | 1 | 2009 | 430 | 0.060 |
Why?
| | Carbon | 1 | 2007 | 203 | 0.060 |
Why?
| | Propane | 1 | 2004 | 2 | 0.050 |
Why?
| | Temperature | 1 | 2007 | 680 | 0.050 |
Why?
| | Animals, Genetically Modified | 1 | 2025 | 245 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2024 | 220 | 0.050 |
Why?
| | Fibromyalgia | 1 | 2004 | 52 | 0.050 |
Why?
| | Organometallic Compounds | 1 | 2004 | 113 | 0.050 |
Why?
| | Mice | 1 | 2020 | 18261 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2024 | 207 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 552 | 0.040 |
Why?
| | Zebrafish | 1 | 2025 | 532 | 0.040 |
Why?
| | Sleep Wake Disorders | 2 | 2004 | 308 | 0.040 |
Why?
| | Software | 1 | 2025 | 695 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 1036 | 0.030 |
Why?
| | Mitochondria | 1 | 2025 | 984 | 0.030 |
Why?
| | Nucleic Acid Denaturation | 1 | 2010 | 32 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2010 | 66 | 0.020 |
Why?
| | Mercaptoethanol | 1 | 2009 | 8 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 19 | 0.020 |
Why?
| | Benzoates | 1 | 2009 | 50 | 0.020 |
Why?
| | Lactones | 1 | 2009 | 59 | 0.020 |
Why?
| | Palladium | 1 | 2004 | 18 | 0.010 |
Why?
| | Phosphines | 1 | 2004 | 18 | 0.010 |
Why?
| | Organoplatinum Compounds | 1 | 2004 | 66 | 0.010 |
Why?
| | Adsorption | 1 | 2004 | 152 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 984 | 0.010 |
Why?
| | Mexico | 1 | 2004 | 234 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2004 | 310 | 0.010 |
Why?
| | Pain Measurement | 1 | 2004 | 554 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 2839 | 0.010 |
Why?
| | Outpatients | 1 | 1999 | 447 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2922 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2419 | 0.010 |
Why?
| | Depression | 1 | 1999 | 1561 | 0.000 |
Why?
| | Middle Aged | 2 | 2004 | 35971 | 0.000 |
Why?
| | Adult | 2 | 2004 | 40489 | 0.000 |
Why?
| | Adolescent | 1 | 2004 | 22409 | 0.000 |
Why?
| | Female | 2 | 2004 | 78304 | 0.000 |
Why?
| | Aged | 1 | 2004 | 25955 | 0.000 |
Why?
|
|
Resendiz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|